Nektar Therapeutics (NKTR) : Artal Group S.a. scooped up 400,000 additional shares in Nektar Therapeutics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 2,000,000 shares of Nektar Therapeutics which is valued at $26.6 Million.Nektar Therapeutics makes up approximately 0.58% of Artal Group S.a.’s portfolio.
Other Hedge Funds, Including , Raymond James Associates boosted its stake in NKTR in the latest quarter, The investment management firm added 2,416 additional shares and now holds a total of 82,696 shares of Nektar Therapeutics which is valued at $1.1 Million.Comerica Bank boosted its stake in NKTR in the latest quarter, The investment management firm added 3,255 additional shares and now holds a total of 138,581 shares of Nektar Therapeutics which is valued at $1.8 Million. Nektar Therapeutics makes up approx 0.02% of Comerica Bank’s portfolio.Oxford Asset Management boosted its stake in NKTR in the latest quarter, The investment management firm added 40,383 additional shares and now holds a total of 268,689 shares of Nektar Therapeutics which is valued at $3.6 Million. Nektar Therapeutics makes up approx 0.13% of Oxford Asset Management’s portfolio.Nationwide Fund Advisors reduced its stake in NKTR by selling 1,392 shares or 1.61% in the most recent quarter. The Hedge Fund company now holds 85,166 shares of NKTR which is valued at $1.1 Million.
Nektar Therapeutics opened for trading at $13.5 and hit $13.96 on the upside on Friday, eventually ending the session at $13.84, with a gain of 3.36% or 0.45 points. The heightened volatility saw the trading volume jump to 8,44,168 shares. Company has a market cap of $1,885,880 M.
On the company’s financial health, Nektar Therapeutics reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.26. The company had revenue of $58.88 million for the quarter, compared to analysts expectations of $43.90 million. The company’s revenue was down -45.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.25 EPS.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Companys research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.